`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`Page 1
`
` UNITED STATES PATENT AND TRADEMARK OFFICE
`
` --------------------
`
` IN THE UNITED STATES PATENT TRIAL AND APPEAL BOARD
`
` --------------------
`
` PRAXAIR DISTRIBUTION, INC.
`
` Petitioner
`
` vs.
`
` INO THERAPEUTICS, LLC, d/b/a IKARIA, INC.
`
` Patent Owner
`
` --------------------
`
` CASE IPR 2015-00884
`
` CASE IPR 2015-00888
`
`12
`
` CASE IPR 2015-00889
`
` CASE IPR 2015-00891
`
` CASE IPR 2015-00893
`
` VIDEOTAPED DEPOSITION OF EXPERT WITNESS
`
` ROBERT T. STONE, Ph.D.
`
` Menlo Park, California
`
` Wednesday, December 2, 2015
`
`Reported by:
`
`ANA M. DUB, RMR, CRR, CCRR
`
`CSR No. 7445
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`www.veritext.com
`
`888-391-3376
`
`Veritext Legal Solutions
`
`Ex. 2020-0001
`
`
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`Page 2
`
` UNITED STATES PATENT AND TRADEMARK OFFICE
`
` --------------------
`
` IN THE UNITED STATES PATENT TRIAL AND APPEAL BOARD
`
` --------------------
`
` PRAXAIR DISTRIBUTION, INC.
`
` Petitioner
`
` vs.
`
` INO THERAPEUTICS, LLC, d/b/a IKARIA, INC.
`
` Patent Owner
`
` --------------------
`
` CASE IPR 2015-00884
`
` CASE IPR 2015-00888
`
`12
`
` CASE IPR 2015-00889
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
` CASE IPR 2015-00891
`
` CASE IPR 2015-00893
`
` Deposition of ROBERT T. STONE, Ph.D., taken on
`
`behalf of Patent Owner INO Therapeutics, LLC, d/b/a
`
`Ikaria, Inc., at the Law Offices of Latham &
`
`Watkins, 140 Scott Drive, Menlo Park, California,
`
`beginning at 9:05 a.m. and ending at 3:02 p.m. on
`
`Wednesday, December 2, 2015, before Ana M. Dub, RMR,
`
`CRR, CCRR, Certified Shorthand Reporter No. 7445.
`
`www.veritext.com
`
`888-391-3376
`
`Veritext Legal Solutions
`
`Ex. 2020-0002
`
`
`
`A P P E A R A N C E S :
`
`Page 3
`
`F o r P e t i t i o n e r P r a x a i r D i s t r i b u t i o n , I n c . :
`
` K & L G A T E S
`
` B Y : B E N J A M I N E . W E E D
`
` A t t o r n e y A t L a w
`
` 7 0 W e s t M a d i s o n S t r e e t , S u i t e 3 1 0 0
`
` C h i c a g o , I l l i n o i s 6 0 6 0 2 - 4 2 0 7
`
` 3 1 2 . 7 8 1 . 7 1 6 6
`
` b e n j a m i n . w e e d @ k l g a t e s . c o m
`
`F o r P a t e n t O w n e r I N O T h e r a p e u t i c s , L L C , d / b / a
`
`I k a r i a , I n c . :
`
` L A T H A M & W A T K I N S L L P
`
` B Y : D A V I D K . C A L L A H A N
`
` A t t o r n e y A t L a w
`
` 3 3 0 N o r t h W a b a s h A v e n u e , S u i t e 2 8 0 0
`
` C h i c a g o , I l l i n o i s 6 0 6 1 1
`
` 3 1 2 . 8 7 6 . 7 7 0 0
`
` d a v i d . c a l l a h a n @ l w . c o m
`
`1
`
`2 3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`1 0
`
`1 1
`
`1 2
`
`1 3
`
`1 4
`
`1 5
`
`1 6
`
`1 7
`
`1 8
`
`1 9
`
`2 0
`
`2 1
`
`2 2
`
`2 3
`
`2 4
`
`2 5
`
`www.veritext.com
`
`888-391-3376
`
`Veritext Legal Solutions
`
`Ex. 2020-0003
`
`
`
`APPEARANCES (Cont.):
`
`Page 4
`
`For Patent Owner INO Therapeutics, LLC, d/b/a
`
`Ikaria, Inc.:
`
` LATHAM & WATKINS LLP
`
` BY: ANDREW J. FOSSUM
`
` Attorney At Law
`
` 811 Main Street, Suite 3700
`
` Houston, Texas 77002
`
` 713.546.7449
`
` andrew.fossum@lw.com
`
`ALSO PRESENT:
`
` Kenneth D. Goetz, Mallinckrodt Pharmaceuticals
`
` Keith Stephens, Videographer
`
`1
`
`2 3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`www.veritext.com
`
`888-391-3376
`
`Veritext Legal Solutions
`
`Ex. 2020-0004
`
`
`
`Page 5
`
` INDEX
`
`WITNESS EXAMINATION
`
`ROBERT T. STONE, Ph.D.
`
` BY MR. CALLAHAN 7
`
` AFTERNOON SESSION 137
`
` BY MR. CALLAHAN (Resumed) 137
`
` BY MR. WEED 175
`
`Number Description Page
`
`Exhibit 2016 United States Patent 168
`
` No. 5,913,309
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8 9
`
`10
`
`11
`
`12
`
`Exhibit 2017 Color Copy of English 158
`
`13
`
` Translation of Exhibit
`
` 1011
`
`Exhibit 2018 Color Copy Blowup of Flip 158
`
` Side of Brochure
`
`Exhibit 2019 Color Copy of Photographs 174
`
` of Praxair Nitric Oxide
`
` Delivery System NoMix
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`www.veritext.com
`
`888-391-3376
`
`Veritext Legal Solutions
`
`Ex. 2020-0005
`
`
`
`Page 6
`
` Menlo Park, California
`
` Wednesday, December 2, 2015
`
` 9:05 a.m.
`
` P R O C E E D I N G S
`
` THE VIDEOGRAPHER: Good morning.
`
` We are going on the record. The time is
`
`9:05 a.m. on today's date, December 2nd, 2015. This
`
`is the video-recorded deposition of Dr. Robert
`
`Stone.
`
` My name is Keith Stephens, here with our
`
`court reporter, Ana Dub. We are here from Veritext
`
`Legal Solutions at the request of the defendant.
`
` This deposition is being held at Latham &
`
`Watkins in Menlo Park, California.
`
` And the caption of the case is
`
`Praxair Distribution, Inc. versus INO Therapeutics,
`
`Inc., and the case numbers are IPR 2015-00884, IPR
`
`2015-00888, IPR 2015-00889, IPR 2015-00891, and IPR
`
`2015-00893.
`
` Will counsel please identify yourselves
`
`and state whom you represent.
`
` MR. CALLAHAN: David Callahan. I am here
`
`on behalf of INO Therapeutics. With me is Andrew
`
`Fossum of Latham & Watkins and Ken Goetz, G-o-e-t-z,
`
`of Mallinckrodt.
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`www.veritext.com
`
`888-391-3376
`
`Veritext Legal Solutions
`
`Ex. 2020-0006
`
`
`
`Page 7
`
` MR. WEED: And Benjamin Weed from
`
`K&L Gates on behalf of the petitioner, Praxair, and
`
`the witness.
`
` THE VIDEOGRAPHER: Thank you.
`
` And the witness may now be sworn in.
`
` ROBERT T. STONE, Ph.D.,
`
`having been administered an oath, was examined and
`
`testified as follows:
`
` EXAMINATION
`
`BY MR. CALLAHAN:
`
` Q Good morning, Dr. Stone. How are you?
`
` A Fine. Thank you.
`
` Q My name is David Callahan. As you've
`
`heard, I'm from Latham & Watkins. We represent
`
`INO Therapeutics, also known as Ikaria in this case.
`
`I'll be taking your deposition today.
`
` Have you given deposition testimony
`
`before?
`
` A I have.
`
` Q So you're familiar with the sort of
`
`general rules of taking -- or giving a deposition?
`
` A Yes.
`
` Q All right. I will ask you -- and I will
`
`www.veritext.com
`
`888-391-3376
`
`Veritext Legal Solutions
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6 7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`Ex. 2020-0007
`
`
`
`Page 8
`
`endeavor myself to not talk over you, for the
`
`benefit of our court reporter, and I'd ask that you
`
`do the same.
`
` If I ask a question that you don't
`
`understand, I take it you will let me know that. Is
`
`that right?
`
` A Yes.
`
` Q And if -- I'm sorry. Let me just step
`
`back.
`
` Have you been retained as an expert in the
`
`matters that the videographer referred to at the
`
`outset, the various procedures of the Patent Office?
`
` A Yes, I have.
`
` Q When were you retained by Praxair?
`
` A I was interviewed. I don't know the exact
`
`date of the retention, but in August of last year.
`
` Q August 2014?
`
` A That's correct.
`
` Q When did you begin your work for them?
`
` A I seriously began the work in October of
`
`2014.
`
` Q And did you -- have you prepared a number
`
`of declarations, one for each of the five
`
`proceedings that were introduced at the outset of
`
`the deposition?
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`www.veritext.com
`
`888-391-3376
`
`Veritext Legal Solutions
`
`Ex. 2020-0008
`
`
`
`Page 9
`
` A Yes.
`
` Q Let's mark those. Actually, they're
`
`already marked.
`
` These are the docs?
`
` Okay. Dr. Stone, I'm going to hand you
`
`what we've marked as -- what has previously been
`
`marked as Praxair 1002.
`
` Okay. And then that is Exhibit 1002 in
`
`the '209 IPR; correct?
`
` A That's what it states here, yes.
`
` Q Okay. Then I'm going to hand you what's
`
`been marked already as Praxair 1002 in the '210 IPR
`
`and 1002 in the '794 IPR, 1002 in the '795 IPR and
`
`1002 in the '904 IPR.
`
` And then, so you've got the corresponding
`
`patents, Dr. Stone, I'm going to hand you what's
`
`been marked as Praxair 1001 in the '209 case --
`
`that's U.S. Patent 8,573,209 -- and what's been
`
`marked as Praxair 1001 in the '210 case -- that's
`
`U.S. Patent No. 8,573,210 -- what's been marked as
`
`Praxair 1001 in the '794 case, which is U.S. Patent
`
`8,776,794; what's been marked as Exhibit 1001 in the
`
`'795 case -- that's U.S. Patent 8,776,795 -- and,
`
`lastly, what's been marked as Exhibit 1001 in the
`
`'904 case, which is U.S. Patent 8,291,904.
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`www.veritext.com
`
`888-391-3376
`
`Veritext Legal Solutions
`
`Ex. 2020-0009
`
`
`
`Page 10
`
` Okay. So you've got each of your five
`
`declarations that you submitted in these five
`
`matters and the corresponding patent in front of
`
`you; is that correct?
`
` A That's correct.
`
` Q With respect to the declarations -- so the
`
`documents that we have marked as 1002 in each of the
`
`respective cases -- do those have all of the expert
`
`opinions that you have reached in this matter to
`
`date?
`
` A To the best of my knowledge, yes.
`
` Q Okay. Is there anything since -- is there
`
`anything you've become aware of -- since you
`
`prepared these declarations in March of this year,
`
`is there anything you've become aware of that you
`
`think further supports the opinions that are
`
`contained in the various Exhibit 1002s?
`
` A Nothing I can think of.
`
` Q Okay. Is there anything that you've seen
`
`in the time since you submitted these declarations
`
`in March of 2015 that you think contradicts or calls
`
`into question any of the opinions that you reached
`
`that are contained in your declarations?
`
` A No.
`
` Q Do your declarations, the various
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`www.veritext.com
`
`888-391-3376
`
`Veritext Legal Solutions
`
`Ex. 2020-0010
`
`
`
`Page 11
`
`Exhibit 1002s, do those disclose all of the
`
`materials that you relied upon in reaching the
`
`opinions that you express in the declarations?
`
` A Outside materials, other than my own
`
`personal knowledge and understanding, that's
`
`correct.
`
` Q Okay. So if I look at the declaration and
`
`add to that your personal knowledge, that
`
`constitutes the universe of materials on which you
`
`relied in reaching your opinions in these matters;
`
`is that correct?
`
` A I believe that's correct.
`
` Q How is it that you obtained the various
`
`prior art materials and technical materials that are
`
`referenced in your declarations?
`
` A Some of the material was given to me by
`
`the attorneys, and some of it I found on my own.
`
` Q Okay. Can you recall for me which of the
`
`materials that you reference in your declarations
`
`you found on your own?
`
` A Don't recall the patent number, but there
`
`is a patent that has to do with respiratory gases
`
`and the -- the necessity of preventing more than one
`
`gas cylinder being used at a time. Very old patent,
`
`requiring a lockout so that two different sources of
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`www.veritext.com
`
`888-391-3376
`
`Veritext Legal Solutions
`
`Ex. 2020-0011
`
`
`
`Page 12
`
`gas could not be used simultaneously.
`
` Q Did you come up with -- or did you
`
`discover any other of the pieces of prior art or
`
`technical materials that are referenced in your
`
`declarations?
`
` A I have to review, but I don't recall any
`
`at this point.
`
` Q Did you -- so the rest of the materials
`
`would have been provided to you by counsel for
`
`Praxair; is that correct?
`
` A Excuse me. I think I need to correct.
`
` I'm not sure whether counsel provided me
`
`with or whether I knew of the infrared communication
`
`standard.
`
` Q Okay. So, again, excepting the infrared
`
`standard and this patent that relates to respiratory
`
`gases, preventing more than one gas from being used
`
`simultaneously, did counsel for Praxair provide you
`
`with the rest of the materials that formed the basis
`
`for the opinions you reached in this case?
`
` A I believe that's correct.
`
` Q Did you ask counsel for Praxair for any
`
`other materials, either specifically or
`
`categorically, to consider in connection with the
`
`preparation of your expert declarations?
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`www.veritext.com
`
`888-391-3376
`
`Veritext Legal Solutions
`
`Ex. 2020-0012
`
`
`
`Page 13
`
` A I do not recall doing so.
`
` Q Is there -- as you sit here today, is
`
`there anything that you feel that you would have
`
`liked to have been able to look at or consider
`
`before preparing your expert declarations in these
`
`five matters?
`
` A Only from the standpoint of the -- my
`
`understanding of fluidics and whether they applied.
`
`And I was asked to keep it restricted, in general,
`
`to therapeutic gas delivery or gas delivery systems
`
`as opposed to fluidics in general.
`
` Q So you were interested in considering the
`
`possible application of fluidics in this matter and
`
`were told to keep it focused only on gases?
`
` A On these patents, yes, that's correct.
`
` Q And you were told that by counsel for
`
`Praxair; is that right?
`
` A I was told the others would probably not
`
`be pertinent. That's correct.
`
` Q Is there any information of any type that
`
`Praxair or any of Praxair's counsel provided you
`
`with that you relied on for your opinions that isn't
`
`disclosed in your report?
`
` A That I relied on for my opinions? No.
`
` Q I've gone through your C.V., Dr. Stone,
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`www.veritext.com
`
`888-391-3376
`
`Veritext Legal Solutions
`
`Ex. 2020-0013
`
`
`
`and am wondering whether you've had any experience
`
`in the course of your career with FDA rules,
`
`regulations, or processes relating to medical
`
`Page 14
`
`devices.
`
` A Yes.
`
` Q I take it from the way you looked at me
`
`when you answered that question that you've had a
`
`pretty fair amount of experience with the FDA as it
`
`pertains to medical devices. Is that right?
`
` A That is correct.
`
` Q Okay. Can you -- based on that
`
`experience, can you just tell me, in your
`
`understanding, what is -- in the FDA world, what's a
`
`Class III medical device?
`
` A Oh. If I don't reverse the orders.
`
` Q I'll give you a hint on this one.
`
` A I think --
`
` Q III is the highest.
`
` A Yeah. Okay. Class III medical devices
`
`would relate to devices that certainly could be
`
`directly implantable devices, things that could have
`
`a severe adverse effect if they fail.
`
` A large number of Class III devices that
`
`I -- some of the Class III devices that I have
`
`worked and/or supervised on have been implantable
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`www.veritext.com
`
`888-391-3376
`
`Veritext Legal Solutions
`
`Ex. 2020-0014
`
`
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`Page 15
`
`valves. Reviewed defibrillators, things of that
`
`nature. Just things that could have an immediate
`
`and severe effect on a person.
`
` Q And then what about Class II? We'll skip
`
`Class I.
`
` A Okay. A lot of the Class II devices --
`
`for example, my first work was with a company called
`
`Nellcor that did pulse oximeters, which can diagnose
`
`hypoxia in a patient. It's probably now one of the
`
`most ubiquitous medical devices that's out there.
`
` Other Class II devices might be devices
`
`for therapies where you could have some harm if they
`
`failed but it's not likely to be severe and adverse
`
`immediately.
`
` Q In the art to which the patents that are
`
`at issue in these proceedings pertain and the
`
`devices that are disclosed in these patents, would
`
`you consider those Class II or Class III --
`
` MR. WEED: Objection to form and scope.
`
`BY MR. CALLAHAN:
`
` Q -- devices?
`
` A I believe that for -- especially since it
`
`was a PMA device as it originally went out, I think
`
`that this is likely to be a Class III device.
`
` Q And you mentioned "PMA." That was
`
`www.veritext.com
`
`888-391-3376
`
`Veritext Legal Solutions
`
`Ex. 2020-0015
`
`
`
`Page 16
`
`actually one of the things I wanted to ask about.
`
`What is "PMA"? What's your understanding of that,
`
`based on your experience in this field?
`
` A I'll have to ask if you want a long or a
`
`short answer.
`
` Q Give me the short one first. Then we'll
`
`see.
`
` A Okay. PMA, premarket approval, is for
`
`devices for which there is no adequate predicate
`
`device, not really sure what the -- what all the
`
`outcomes are to be. It allows a great deal more
`
`monitoring, a number of changes. Any change
`
`requires a very careful review by the FDA before
`
`it's allowed.
`
` It's just a higher level of attention that
`
`the FDA pays because there's not enough experience
`
`with the device. It's not a pre-1976, or a device
`
`that's had several 510(k)s, or several others have
`
`been issued before the FDA will approve it.
`
` Q Okay. And then so this is, somebody wants
`
`to do something new in the medical device space,
`
`sufficiently new that the FDA says: We better take
`
`a real close look at this. Is that right?
`
` A That's correct.
`
` Q Okay. And then you mentioned 510(k).
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`www.veritext.com
`
`888-391-3376
`
`Veritext Legal Solutions
`
`Ex. 2020-0016
`
`
`
`Page 17
`
`What -- in your years of experience in this field,
`
`what's the 510(k) process in the FDA world?
`
` A Sure. For devices that are very similar
`
`to devices that are on the market -- "substantially
`
`equivalent" is the term that the FDA utilizes.
`
` One can produce evidence to the FDA that a
`
`new device is substantially equivalent to a prior
`
`device. And the FDA has guidelines for helping
`
`determine what "substantial equivalence" is. Then
`
`the device can -- you can notify the FDA that it's
`
`going to be marketed.
`
` Provided enough information, the FDA can
`
`determine whether, indeed, it is a substantially
`
`equivalent device to either a pre-1976 or to a
`
`device that's had multiple sources and multiple
`
`approvals in the past.
`
` Then the device can go through a less
`
`rigorous process prior to marketing the device.
`
` Q And have you, in your career, taken
`
`medical devices through PMA approval, premarket
`
`approval?
`
` A I have worked on devices that went through
`
`PMA. I did not direct the guidance through PMAs.
`
` Q But you've worked on devices that were
`
`going through PMAs?
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`www.veritext.com
`
`888-391-3376
`
`Veritext Legal Solutions
`
`Ex. 2020-0017
`
`
`
` A That's correct.
`
` Q And is the same true with respect to
`
`Page 18
`
`510(k) approvals?
`
` A Yes.
`
` Q I take it in connection with --
`
` A Sorry. It's more extensive than that.
`
` And with regard to 510(k)s, I've actually
`
`written them and sheltered them through --
`
`shepherded them through. Sorry.
`
` Q I take it, in connection with the 510(k)
`
`approval process, then, you've taken a look at
`
`predicate devices to determine whether and the
`
`extent to which you could use those to support a
`
`510(k) request?
`
` A Yes.
`
` Q And have also had experience determining
`
`whether and the extent to which a product at issue
`
`is a substantial equivalent to a predicate device?
`
` A Yes.
`
` Q All right. I just -- I take it from the
`
`amount of experience you've had here, that this
`
`regulatory approval scheme is a pretty
`
`predominant -- or prominent, maybe I should say, in
`
`the design and manufacture of medical devices.
`
`Would you agree with that?
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`www.veritext.com
`
`888-391-3376
`
`Veritext Legal Solutions
`
`Ex. 2020-0018
`
`
`
`Page 19
`
` A Yes.
`
` Q How, if at all, does the regulatory
`
`scheme -- premarket approval, 510(k) approvals,
`
`looking for predicate devices, et cetera -- how does
`
`that affect, in your experience, the way that people
`
`design medical devices?
`
` A The actual design of the medical device
`
`itself is regulated by the FDA in that a fully
`
`documented process has to be incorporated from the
`
`time the device begins the productization phase.
`
` From the design standpoint, if one is
`
`inventing in another field, one can simply come up
`
`with a solution and start working on it and go to
`
`town.
`
` If one is trying to come up with a design
`
`for something in the medical field, one needs to
`
`look at what all the regulatory issues would be to
`
`be sure that the device, as designed and as built,
`
`is likely to be approved by the FDA.
`
` Q So what does that entail? So if I'm
`
`coming out with a medical device and I don't get the
`
`opportunity, in your words, to just go to town as I
`
`might if I were designing a computer or something
`
`else, what are the constraints that the regulatory
`
`environment places on you as a product designer?
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`www.veritext.com
`
`888-391-3376
`
`Veritext Legal Solutions
`
`Ex. 2020-0019
`
`
`
`Page 20
`
` A Me, as a product designer, typically, as I
`
`begin the design process, I'll come up with a
`
`definition of the problem, how I would like to solve
`
`it. I will look to see whether there are predicate
`
`devices and what process I'm likely to need to
`
`follow. I might consult so-called regulatory
`
`bodies, testing labs, and so forth, to find out what
`
`their concepts are. Incorporate all of those issues
`
`into the very beginning of the documentation process
`
`before I would actually even begin the design.
`
` I have a whole presentation that I do for
`
`clients, when it comes to doing a medical product
`
`design, to show that we can have an FDA-compliant
`
`design process. But that's a half-hour
`
`presentation.
`
` Q But at the end of the day, you go into
`
`this process making sure that you've got a
`
`product -- or you're going to end up with a product
`
`that is going to get regulatory approval; correct?
`
` A Yes.
`
` Q And in your experience, is what you just
`
`described as your own personal experience, is that
`
`the way that medical products are generally
`
`designed?
`
` A That's the way by law it should be
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`www.veritext.com
`
`888-391-3376
`
`Veritext Legal Solutions
`
`Ex. 2020-0020
`
`
`
`Page 21
`
`designed here in the United States. And there's a
`
`similar process for Europe, for Canada, for Japan,
`
`for China.
`
` Q Do product designers in the medical device
`
`field, do they use materials that have already been
`
`filed with the FDA, or products that have already
`
`been approved, as guidance to help them design
`
`products that are safe and effective for use?
`
` A In my experience, yes.
`
` Q I want to go back to what you described as
`
`the first step in your process, which is -- and if I
`
`got this wrong, you should feel free to correct me
`
`because I'm going from my chicken scratch notes
`
`here.
`
` But it sounded like the first step in your
`
`process is determining what the problem is. Is that
`
`right?
`
` A That's correct.
`
` Q Okay. How is it -- as a designer of
`
`products in the medical device field, how is it that
`
`you go about figuring out what the problem is that
`
`you're looking to address?
`
` A I can only answer that from a personal
`
`standpoint.
`
` I review a lot of medical literature,
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`www.veritext.com
`
`888-391-3376
`
`Veritext Legal Solutions
`
`Ex. 2020-0021
`
`
`
`Page 22
`
`publications describing what's happening in medicine
`
`on a daily basis. I look at what the marketplace is
`
`looking for, what are the problems that need to be
`
`solved. And from reviewing the various
`
`technologies, can I somehow take that technology,
`
`modify it, and solve a problem that's out there.
`
` I don't believe in finding a solution,
`
`then going out and looking for a problem. I believe
`
`in finding a problem, then looking for a solution.
`
` Q And what do you -- when you're reviewing
`
`the medical literature, as you described, reviewing
`
`the marketplace information, can you give me some
`
`examples of things that you see where you have the
`
`"aha" moment of at least what the problem is that
`
`needs to be solved?
`
` A Best example would be a personal example
`
`from years ago.
`
` One of the problems with pulse oximetry is
`
`that it was susceptible to motion artifact and
`
`generated a lot of alarms in an area where it ought
`
`to be quiet and the alarms weren't necessary. So I
`
`looked at various signal processing techniques and
`
`ended up filing patents that related to both the
`
`accuracy and the -- helping to immunize the devices
`
`against those alarms.
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`www.veritext.com
`
`888-391-3376
`
`Veritext Legal Solutions
`
`Ex. 2020-0022
`
`
`
`Page 23
`
` So finding out that there's a
`
`problem: too much stimulus in a nursery. How do
`
`we reduce that, and how -- by making the device work
`
`better and solving the problem.
`
` Q And so you would have found out about that
`
`by reading literature that says: We've got this
`
`nursery; these kids are supposed to be sleeping; and
`
`one or more of the kids is alarming their pulse
`
`oximeter every ten minutes and nobody can get any
`
`sleep.
`
` A In that particular instance, it was both
`
`by looking at public data and actually visiting a
`
`neonatal intensive care unit and confirming that
`
`that was the case.
`
` Q And is that -- in your experience, the way
`
`that you identify problems, is that consonant with
`
`the way you see, or have seen in your career, other
`
`designers of medical devices figuring out their
`
`start point or figuring out what the problem is?
`
` A That's one of the ways. Another way is
`
`clinicians who come to us with an idea. They found
`
`a problem, and they would like a solution.
`
` Q Any other ways that you go about this
`
`first step of identifying what the problem is?
`
` A I can't tell you all the things that
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`www.veritext.com
`
`888-391-3376
`
`Veritext Legal Solutions
`
`Ex. 2020-0023
`
`
`
`Page 24
`
`trigger the "aha." Sometimes it's simply reading
`
`something and noting; noting that it might apply
`
`from one field to another.
`
` The inventive process typically is finding
`
`out what the problems are and then, hopefully,
`
`you'll have a mind that has a broad enough funnel
`
`that, as things come into it, you'll see how those
`
`might apply and how it might be modified.
`
` Q Okay. What sources are you aware of for
`
`people in your field, designers of medical devices,
`
`what sources are available to you folks to identify,
`
`let's start with, safety issues with medical
`
`devices?
`
` A Oh, I believe there's AAMI, the American
`
`Association of Medical Instruments, some of their
`
`guidelines and publications that they have with
`
`regard to safety. They have conferences.
`
` I attend such conferences and medical
`
`device conferences, seeing what's on. I haven't for
`
`a while, but certainly used to attend the American
`
`Society of Anesthesiology, and looking at their
`
`publications. All kinds of sources of that nature.
`
` Q Are there any -- besides going to
`
`conferences or looking at these publications, any
`
`other sources for designers of medical devices to
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`www.veritext.com
`
`888-391-3376
`
`Veritext Legal Solutions
`
`Ex. 2020-0024
`
`
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`Page 25
`
`identify existing and maybe unmet problems with
`
`medical devices?
`
` A There's a lot of publications and a lot of
`
`online publications. I personally get about a dozen
`
`each day that I look through to look at what the
`
`problems are, what the potential -- what new
`
`solutions there might be, how a solution might be
`
`applied to one particular medical problem and I know
`
`of another.
`
` And, frankly, I know a number of
`
`clinicians, including two that are on my board of
`
`directors, and a son, who is not, who's a clinician,
`
`that I can discuss those and potential solutions
`
`with.
`
` I think that typically, an engineer, a
`
`designer, would want to have access to that kind of
`
`information before beginning the process.
`
` Q Would or would not?
`
` A Would.
`
` Q Okay.
`
` A Yes.
`
` Q Yeah. You'd want to have some -- as you
`
`said, you're not looking for solutions to problems
`
`that don't exist; right? You're looking for
`
`problems and then trying to figure out solutions to
`
`www.veritext.com
`
`888-391-3376
`
`Veritext Legal Solutions
`
`Ex. 2020-0025
`
`
`
`Page 26
`
`them; right?
`
` A That's correct.
`
` Q So I'm just trying to figure out in a
`
`little more detail what the source material can be
`
`for the problems.
`
` Does the FDA have any available data,
`
`information, anything like that, to help you learn
`
`about existing problems with medical devices?
`
` A The FDA has a database of failures that
`
`have been reported with regard to devices. I don't
`
`know about lists of other, what I refer to as,
`
`clinical problems.
`
` Q And what is that -- what is the FDA
`
`database to which you're referring?
`
` A It's referred to as the MAUDE database.
`
` Q So you could look -- a product designer
`
`could look for the particular product or products in
`
`which they're interested and see what kinds of
`
`device failures are reported up into the MAUDE
`
`database and use that as a source for figuring out
`
`if there's a problem to be addressed; is that right?
`
` A That's a possibility. I personally doubt
`
`that that would be as efficacious as some of the
`
`broad-based problems that are out there.
`
` Q So you're really looking for the people --
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`www.veritext.com
`
`888-391-3376
`
`Veritext Legal Solutions
`
`Ex. 2020-0026
`
`
`
`Page 27
`
`to use an expression -- who have got their feet on
`
`the ground dealing with patients, to be reporting
`
`these kinds of issues or problems or challenges that
`
`they're having. Is that fair?
`
` A Very much so.
`
` Q Okay. Let me ask -- let me turn the page
`
`a little bit, both literally here and figuratively,
`
`and ask about your experience with gases generally.
`
` I know you covered some of this in your
`
`report, and there's some things mentioned in your
`
`C.V. But give me an overview of what your
`
`experience is with different gases that are used in
`
`the medical field.
`
` A First direct experience was with
`
`anesthesia machines which delivered oxygen and
`
`anesthetic gases.
`
` Various types of anesthetic circuits.
`
`Took one and modified it to drive a tonometer that I
`
`had designed in my early work at Nellcor in order to
`
`adjust blood oxygen levels to different levels for
`
`testing out measurements.
`
` Helped develop carbon dioxide sensors that
`
`would be utilized in such environments for measuring
`
`end-tidal CO2 more conveniently and more readily.
`
` Attempting to solve problems in the
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`www.veritext.com
`
`888-391-3376
`
`Veritext Legal Solutions
`
`Ex. 2020-0027
`
`
`
`Page 28
`
`positioning of trach tubes, which an infrequent but
`
`very damaging circumstances where the esophagus is
`
`